Advertisement
UK markets closed

  • FTSE 100

    8,213.49
    +41.34 (+0.51%)
     

  • FTSE 250

    20,164.54
    +112.24 (+0.56%)
     

  • AIM

    771.53
    +3.42 (+0.45%)
     

  • GBP/EUR

    1.1671
    +0.0019 (+0.17%)
     

  • GBP/USD

    1.2584
    +0.0037 (+0.30%)
     

  • Bitcoin GBP

    50,946.84
    +314.50 (+0.62%)
     

  • CMC Crypto 200

    1,386.80
    +74.17 (+5.65%)
     

  • S&P 500

    5,127.79
    +63.59 (+1.26%)
     

  • DOW

    38,675.68
    +449.98 (+1.18%)
     

  • CRUDE OIL

    78.84
    +0.73 (+0.93%)
     

  • GOLD FUTURES

    2,323.90
    +15.30 (+0.66%)
     

  • NIKKEI 225

    38,236.07
    -38.03 (-0.10%)
     

  • HANG SENG

    18,578.30
    +102.38 (+0.55%)
     

  • DAX

    18,194.02
    +192.42 (+1.07%)
     

  • CAC 40

    8,032.00
    +74.43 (+0.94%)
     

Gene therapy takes step forward as GSK files for EU approval

Reuters - UK Focus

LONDON, May 5 (Reuters) - GlaxoSmithKline (Other OTC: GLAXF - news) said on Tuesday it had submitted a gene therapy for approval in Europe, becoming the first big drugmaker to seek marketing authorisation for the technology to fix faulty genes.

Reuters reported last week that the move was imminent. It marks the latest sign of a renaissance in gene therapy after some disastrous clinical trial results in the late 1990s and early 2000s.

GSK's product, developed with Italian scientists, is designed to treat a tiny number of children with ADA Severe Combined Immune Deficiency (ADA-SCID) for whom no suitable bone marrow donor can be found.

(Reporting by Ben Hirschler; editing by Jason Neely)